808 related articles for article (PubMed ID: 19594290)
1. Rural residence and prostate cancer screening with prostate-specific antigen.
Stamatiou K; Skolarikos A
Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
3. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
[TBL] [Abstract][Full Text] [Related]
6. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
8. The Japanese guideline for prostate cancer screening.
Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
Lim LS; Sherin K;
Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
[TBL] [Abstract][Full Text] [Related]
10. PSA screening and prostate cancer mortality.
Perron L; Moore L; Bairati I; Bernard PM; Meyer F
CMAJ; 2002 Mar; 166(5):586-91. PubMed ID: 11898936
[TBL] [Abstract][Full Text] [Related]
11. Breast, colon, and prostate screening in the adult population of Croatia: does rural origin matter?
Polasek O; Kolcic I; Voncina L; Strnad M; Vuletic S; Kern J
Rural Remote Health; 2007; 7(3):749. PubMed ID: 17900222
[TBL] [Abstract][Full Text] [Related]
12. [The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].
Bonneux L
Ned Tijdschr Geneeskd; 2005 Apr; 149(18):966-71. PubMed ID: 15903036
[TBL] [Abstract][Full Text] [Related]
13. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Shteynshlyuger A; Andriole GL
J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
[TBL] [Abstract][Full Text] [Related]
15. Should prostate-specific antigen screening be offered to asymptomatic men?
van Vugt HA; Bangma CH; Roobol MJ
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
[TBL] [Abstract][Full Text] [Related]
16. [PSA related screening of prostate cancer. Panic or improvement?].
Fornara P; Jurczok A
Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen: a useful screening test?
Concato J
Cancer J; 2000 Apr; 6 Suppl 2():S188-92. PubMed ID: 10803835
[TBL] [Abstract][Full Text] [Related]
18. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
Colli JL; Amling CL
Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
[TBL] [Abstract][Full Text] [Related]
20. [Screening for prostate cancer--what does the evidence show?].
Borre M; Iversen P
Ugeskr Laeger; 2007 May; 169(20):1887-8. PubMed ID: 17553362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]